YONDELIS®

Phase II clinical trial of ET-743 as 2nd or 3rd line treatment in patients with advanced stage and/or metastatic soft tissue sarcoma

Posted on March 15, 2018 by tsuperadmin -

NCT00796120 – An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)

Posted on March 15, 2018 by tsuperadmin -

NCT00579501 – Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma

Posted on March 15, 2018 by tsuperadmin -

Phase 2 study of ET-743 as second or third line therapy in advanced and/or metastatic soft tissue sarcoma patients

Posted on March 15, 2018 by tsuperadmin -

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

Posted on March 15, 2018 by tsuperadmin -

Phase II study on ET-743 in advanced soft tissue sarcomas of the adult (excluding gastrointestinal stroma cell tumors – GIST)

Posted on March 15, 2018 by tsuperadmin -

NCT00786838 – A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

Posted on August 24, 2017 by tsuperadmin -

NCT00210665 – A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

Posted on August 24, 2017 by tsuperadmin -

NCT00060944 – A Randomized, Multicenter, Open-label Study of Yondelis (ET-743 Ecteinascidin) Administered by 2 Different Schedules (Weekly for 3 of 4 Weeks vs. q3 Weeks) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment With an Anthracycline and Ifosfamide

Posted on August 24, 2017 by tsuperadmin -

NCT01343277 – A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Posted on August 24, 2017 by tsuperadmin -